Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triweekly Cetuximab + Capecitabine Maintenance in mCRC
NCT05775900Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2023
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Started Feb 2023; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05775900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775900.